Allogene therapeutics, inc. (ALLO)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-207,488

-184,594

-154,073

-146,835

-240,494

-211,505

0

0

0

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock-based compensation

52,411

46,063

38,060

29,864

26,433

18,566

0

0

0

Amortization of other intangible assets acquired

603

603

602

602

603

452

0

0

0

Depreciation and amortization

5,773

4,424

3,117

2,292

1,592

1,048

0

0

0

Net amortization/accretion on investment securities

2,580

3,596

4,297

3,321

2,259

1,036

0

0

0

Non-cash rent expense

6,220

6,777

5,995

3,380

3,107

1,832

0

0

0

Benefit from income taxes

0

-

0

0

0

-

0

0

0

Share of losses from equity method investments

0

-

-

-

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

1,001

5,445

5,380

8,782

10,495

8,598

0

0

0

Other long-term assets

4,243

4,374

1,639

2,237

432

244

0

0

0

Accounts payable

-1,681

-985

2,580

8,864

8,452

8,800

0

0

0

Accrued and other current liabilities

6,533

6,351

6,953

-553

5,446

12,138

0

0

0

Other long-term liabilities

-2,415

-2,425

-1,991

-1,282

-711

0

0

0

0

Net cash used in operating activities

-147,903

-137,350

-108,564

-93,759

-74,914

-44,653

0

0

0

Cash flows from investing activities:
Purchases of property and equipment

52,621

50,791

38,000

20,977

13,657

3,234

0

0

0

Proceeds from maturities of investments

497,131

472,578

375,000

216,650

114,943

19,235

0

0

0

Purchase of investments

323,246

252,628

496,839

751,063

701,704

649,307

0

0

0

Net cash (used in) provided by investing activities

116,189

164,084

-157,233

-552,784

-599,910

-632,798

0

0

0

Cash flows from financing activities:
Proceeds from issuance of common stock, net of commissions and issuance costs

0

-

-

-

0

-

-

-

-

Proceeds from issuance of common stock and upon exercise of stock options

3,261

2,958

0

0

0

-

-

-

-

Proceeds from issuance of common stock under the employee stock purchase plan

2,537

1,783

1,783

684

684

0

0

0

0

Net cash provided by financing activities

74,862

58,960

347,008

619,499

771,866

771,182

0

0

0

Net change in cash, cash equivalents and restricted cash

43,148

85,694

81,211

-27,044

97,042

93,731

0

0

0

Non-cash investing activities:
Property and equipment purchases in accounts payable and accrued liabilities

3,742

4,668

9,549

16,789

8,316

3,182

0

0

0

Supplemental disclosure:
Cash paid for amounts included in the measurement of lease liabilities

4,568

3,563

2,213

1,187

422

31

0

0

0

Cash received for amounts related to tenant improvement allowances from lessors

0

-

-

-

0

-

-

-

-